In a Phase I trial (NCT05084365) involving patients with TP53-mutated CLL, systemically delivered miR-34a-containing sEVs have shown potential to reduce PD-L1 expression, suppress oncogenes, and promote immune activation 62. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.